Diabetes
Refine Search
Pharmaceutical
German family-owned drug major Boehringer Ingelheim and US pharma major Eli Lilly (NYSE: LLY) have enrolled the first patient in a new cardiovascular and renal outcomes trial for Trajenta (linagliptin) in type 2 diabetes. 1 August 2013
Pharmaceutical
Japan's largest drugmaker, Takeda Pharmaceutical (TYO: 4502), says that the China Food and Drug Administration (CFDA) has issued an Import Drug License (IDL) for Nesina (alogliptin) for the treatment of type 2 diabetes. 31 July 2013
Biotechnology
French biotech firm Adocia (Euronext Paris: ADOC) has agreed with US pharma major Eli Lilly (NYSE: LLY) not to continue further joint research under the licensing agreement signed in December 2011 relating to use of Adocia's BioChaperone technology for the formulation of fast acting insulin analog formulated with the BioChaperone technology. Consequently, the two companies have terminated the collaboration. 30 July 2013
Pharmaceutical
Japan's largest drugmaker Takeda (TSE: 4502) has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for three new type 2 diabetes therapies. 29 July 2013
Pharmaceutical
Having finalized a review of glucagon-like peptide 1 (GLP-1)-based diabetes therapies, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that presently available data do not confirm recent concerns over an increased risk of pancreatic adverse events with these medicines. 26 July 2013
Generics
US drugmaker Perrigo (Nasdaq: PRGO; TASE) says it has received tentative approval from the US Food & Drug Administration for its Abbreviated New Drug Application for repaglinide tablets, the generic equivalent to Prandin tablets (repaglinide tablets). 22 July 2013
Pharmaceutical
There are hints of a minor added benefit of US drug giant Merck & Co's (NYSE: MRK) Januvia (sitagliptin) in free combination with metformin versus sulfonylureas if the treatment goal is to lower blood glucose to near-normal levels, according to the German Institute for Quality and Efficiency in Health Care (IQWiG). In comparison with the sulfonylurea glipizide, which is not approved in Germany, the added benefit in men is even "major," it noted. 15 July 2013
Pharmaceutical
Swiss drug major Roche (ROG: SIX) revealed this morning (July 10)that it is terminating the Phase III AleCardio study and all other trials of its diabetes drug candidate aleglitazar following the results of a regular safety review. As a result of this, the independent Data and Safety Monitoring Board (DSMB) has recommended halting the trial due to safety signals and lack of efficacy. 10 July 2013
Pharmaceutical
US drug major Eli Lilly (NYSE: LLY) and family-owned German pharma firm Boehringer Ingelheim today (July 8) announced that their marketing authorization application (MAA) for an investigational basal insulin for the treatment of type 1 and type 2 diabetes has been accepted for review by the European Medicines Agency. 8 July 2013
Pharmaceutical
Pipeline anti-diabetic drugs, including products from US drug major Eli Lilly (NYSE: LLY) and French drug major Sanofi (Euronext: SAN), have "great potential," according to independent analysts at Datamonitor Healthcare, following this year's American Diabetes Association (ADA) meeting in Chicago. 4 July 2013
Pharmaceutical
Premium-priced DPP-IV inhibitors and GLP-1 analogues used in the treatment of type 2 diabetes lack nationwide government coverage in Brazil, Mexico and Argentina. Government-sponsored diabetes programs and most Social Funds (Obras Sociales) do not provide any coverage/reimbursement to these agents in Argentina, according to a new report of health care advisory firm Decision Resources. 3 July 2013
Generics
Indian drugmaker Intas Pharmaceuticals and its wholly owned subsidiary Accord Healthcare have entered into a settlement and license agreement with Swiss pharma major Roche (ROG: ROG) that will resolve pending patent litigation related to Xeloda (capecitabine), used in the treatment of metastatic breast and colorectal cancers. 25 June 2013
Biotechnology
US biotech firm Isis Pharmaceuticals (Nasdaq: ISIS) saw its shares leap as much as 22% to $26.89 on Monday, after the company revealed that it investigation drug reduced triglycerides in blood and increased the level of "good" cholesterol. 25 June 2013
Pharmaceutical
Continued news from the 73rd Scientific Sessions of the American Diabetes Association being held in Chicago, includes presentations from US drug majors Eli Lilly (NYSE: LLY), Johnson & Johnson (NYSE: JNJ) and the UK's GlaxoSmithKline (LSE: GSK). 24 June 2013
Pharmaceutical
Among presentations over the weekend at the 73rd Scientific Sessions of the American Diabetes Association being held in Chicago, Danish insulin giant Novo Nordisk (NOV: N) revealed new data from a one-year extension trial on Tresiba (insulin degludec), showing that type 2 diabetes patients receiving Tresiba have statistically significant better health-related quality of life compared to patients receiving insulin glargine. The data are from the BEGINTONCE LONG trial and showed that the drug also significantly lowered rates of nocturnal confirmed hypoglycemia compared to patients receiving insulin glargine. 24 June 2013
Pharmaceutical
German family-owned Boehringer Ingelheim and US partner Eli Lilly (NYSE: LLY) revealed yesterday (June 20) that the US Food and Drug Administration has approved updates to the full prescribing information (PI) for their diabetes drugs Tradjenta (linagliptin) and Jentadueto (linagliptin and metformin hydrochloride) tablets. 21 June 2013
Pharmaceutical
Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502) says that its new diabetes products Nesina (alogliptin), a dipeptidyl peptidase-4 inhibitor (DPP-4i), and the fixed-dose combination therapies Kazano (alogliptin and metformin HCl) and Oseni (alogliptin and pioglitazone) are now available by prescription in pharmacies in the USA. All three drugs were approved early this by the Food and Drug Administration for the treatment of type 2 diabetes in adults, as adjuncts to diet and exercise (The Pharma Letter January 28). 20 June 2013
Generics
Avoidable costs of more than $200 billion are incurred each year in the US health care system as a result of medicines not being used responsibly by patients and health care professionals, according to a new study released yesterday June 19) by the IMS Institute for Healthcare Informatics. This represents 8% of the country's total annual health care expenditures and amounts to millions of avoidable hospital admissions, outpatient treatments, pharmaceutical prescriptions and emergency room visits for patients. 20 June 2013
Pharmaceutical
Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US partner Bristol-Myers Squibb have announced mixed top-line results of the Phase IV SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of diabetes drug Onglyza (saxagliptin). 19 June 2013
Pharmaceutical
Denmark’s Novo Nordisk and Valo Health today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo’s extensive human dataset and computation powered by artificial intelligence (AI). 8 January 2025
Biotechnology
The past year has been a very busy one for privately-held Dewpoint Therapeutics, a Boston firm founded in 2018 that focuses on the application of biomolecular condensate biology towards the development of a new generation of therapeutics to address diseases of high unmet need. 7 January 2025
Pharmaceutical
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033. 2 January 2025
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze